Spots Global Cancer Trial Database for portal hypertension
Every month we try and update this database with for portal hypertension cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma | NCT00280007 | Hepatocellular ... | bevacizumab | 18 Years - 85 Years | Medical University of Vienna | |
| Relevance of Sarcopenia in Advanced Liver Disease | NCT05502198 | Liver Cirrhosis Hepatocellular ... Sarcopenia Portal Hyperten... | 18 Years - | Linkoeping University | ||
| A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC) | NCT01451658 | Gastroesophagea... Hepatocellular ... | propranolol | 18 Years - 80 Years | Taipei Veterans General Hospital, Taiwan | |
| A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC) | NCT01451658 | Gastroesophagea... Hepatocellular ... | propranolol | 18 Years - 80 Years | Taipei Veterans General Hospital, Taiwan | |
| CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302) | NCT05704192 | Hepatocellular ... Portal Hyperten... | TACE ± Systemic... | 18 Years - | Zhongda Hospital | |
| Gastroesophageal Varices in Cavernoma | NCT04525768 | Gastroesophagea... Myeloproliferat... Portal Caver Ca... Portal Hyperten... | JAK2 mutation t... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| HR Versus RFA for HCC in Patients With PHT | NCT02192671 | Carcinoma, Hepa... Liver Neoplasms Neoplasms, Glan... | Hepatic Resecti... Radiofrequency ... | 18 Years - 75 Years | Guangxi Medical University | |
| A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC) | NCT01451658 | Gastroesophagea... Hepatocellular ... | propranolol | 18 Years - 80 Years | Taipei Veterans General Hospital, Taiwan | |
| Hepatic and Systemic Hemodynamic Modeling During Liver Surgery | NCT05339984 | Liver Diseases Liver Transplan... | Partial hepatec... liver transplan... Portal vein emb... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | NCT05027425 | Hepatocellular ... Cirrhosis Portal Hyperten... | Durvalumab Tremelimumab Liver Transplan... | 18 Years - | University of Cincinnati | |
| Oxaliplatin-induced Portal Hypertension | NCT04524676 | Gastroesophagea... Colorectal Canc... Received Oxalip... | Individualized ... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Anticoagulation in Gastroesophageal Varices and JAK2 Mutation | NCT04527666 | Gastroesophagea... JAK2 Mutation Myeloproliferat... | Anticoagulation... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Management of Oxaliplatin-related Gastroesophageal Variceal Bleeding | NCT05141617 | Gastroesophagea... Gastrointestina... Received Oxalip... | Endoscopic trea... TIPS | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302) | NCT05704192 | Hepatocellular ... Portal Hyperten... | TACE ± Systemic... | 18 Years - | Zhongda Hospital | |
| Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | NCT05027425 | Hepatocellular ... Cirrhosis Portal Hyperten... | Durvalumab Tremelimumab Liver Transplan... | 18 Years - | University of Cincinnati |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
